

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

GENENT.091NP

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vanessa Hsei, et al.

Appl. No. : ~~09/335,014~~ 09/355,014

Filed : September 13, 1999

For : ANTIBODY FRAGMENT-
POLYMER CONJUGATES
ABD HUMANIZED ANTI-IL-8
MONOCLONAL ANTIBODIES

) Group Art Unit 1642

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first-class mail in
) an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
) 20231, on

January 11, 2002

(Date)

Günther R. Dreger, Reg. No. 33,055

Examiner : L. Helms

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

Commissioner for Patents
Washington, D.C. 20231
ATTENTION BOX: AF

Dear Sir:

This is in response to the final Office Action mailed on December 19, 2001 (Paper No. 14) in connection with the above-identified patent application. Please amend this application as follows.

In the Claims:

Please cancel claims 5 and 14, without prejudice.

Please amend claims 1 and 6 to read as follows:

1. (Amended) A conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous molecules, wherein the apparent size of the conjugate is (a) at least about 500 kD, and (b) at least 8 fold greater than the apparent size of the antibody fragment.

6. (Amended) The conjugate of claim 1, wherein the apparent size of the conjugate is at least 15 fold greater than the apparent size of the antibody fragment.